Changes in voice patterns for monitoring heart failure deterioration

Chaim Lotan^{1*}, MD; Offer Amir^{1,2}, MD; Ronit Haviv³, PhD; Ilan Shallom³, PhD; William T. Abraham⁴, MD

1. Heart Center, Hadassah Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel; 2. Azrieli Faculty of Medicine, Bar-Ilan University, Tzfat, Israel; 3. Cordio Medical, Or Yehuda, Israel; 4. The Ohio State University Wexner Medical Center, Columbus, OH, USA



Figure 1. *HearO application*.

*Corresponding author: Heart Center, Hadassah Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel. E-mail: chaim.lotan@gmail.com

Heart failure (HF) affects >6 million adults in the United States¹ and 26 million worldwide², at a cost of over \$30 billion in the United States alone³. Pulmonary congestion is the predominant factor leading to hospitalisation for HF patients, and also is a major contributor to poor outcomes after hospital discharge. A need exists for a simple, non-invasive approach to detecting worsening pulmonary congestion at an early stage for the management of HF patients. In the context of pulmonary congestion, it has been proposed that the fluid overload may be detected by distinctly altered phonation patterns. A novel speaker verification and speech processing technology has been developed that uses a proprietary smartphone application (HearO, Cordio Medical). The speech analysis is based on the paradigm of text-dependent speaker verification. The premise behind the HearO system is that subtle physiological changes associated with HF decompensation affect the patient's speech, producing a different voiceprint. These changes are much more subtle than those found between different speakers but are nonetheless detectable using algorithms derived from those used in text-dependent speaker verification (Figure 1).

To evaluate whether distinct speech measures reflect different clinical states of pulmonary congestion, two single-arm, open label, non-invasive studies were undertaken to analyse speech recordings of HF patients, one in hospitalised patients with acute decompensated HF (ADHF) and one in ADHF patients undergoing haemodialysis (a model which represents a fluid-controlled environment).

Patients hospitalised for ADHF consistent with pulmonary congestion were studied⁴. Forty-seven patients were enrolled, and approximately 40 recordings were obtained from each patient, resulting in a total of 1,728 recordings. Recordings were analysed for 5 chosen distinct HearO speech measures (SM). Interpatient comparisons of collected recordings identified significant differences in all 5 tested SM of both clinical states, wet (admission) vs dry (discharge); p<0.0001, showing a mean percentage change from baseline ranging from 49% to 200%.

In another study, five patients with congestive HF undergoing haemodialysis three times per week for 3 months were studied⁵. A total of 472 speech recordings (mean 94.4 per patient) were analysed. Mean baseline (predialysis) speech measures increased by approximately 23% by the end of the dialysis session and remained at a similar level until the following morning. By the day after dialysis, mean speech measures had returned to predialysis levels (just before the next dialysis cycle). The results also showed a significant (p=0.04) difference between median speech measures immediately before versus after dialysis, and a significant (p=0.007) difference versus those obtained the following morning.

These two studies were able to identify voice alterations, reflective of changes in HF clinical status (wet vs dry), among patients with ADHF and in chronic congestive HF patients undergoing haemodialysis, with a significant shift toward improvement and return to baseline between all dialysis cycles. This innovative approach assessing HF may provide a new tool for in-hospital and remote monitoring of pulmonary congestion in HF patients. If validated in additional studies, this speech-based analysis could provide a simple non-invasive approach to the remote monitoring and management of patients with HF.

Acknowledgements

The authors would like to acknowledge the assistance of Richard Perry in the preparation of this manuscript, which was supported by Cordio Medical.

Conflict of interest statement

O. Amir is a paid consultant for Cordio Medical Ltd.; W. T. Abraham has received consulting fees from Abbott, Boehringer Ingelheim, CVRx, Edwards Lifesciences, and Respicardia; salary support from V-Wave Medical and research support from the U.S. National Institutes of Health/National Heart, Lung, and Blood Institute. I. Shallom is the Chief Technology Officer of Cordio Medical. C. Lotan is a board member of Cordio Medical and has received lectures fees from Boehringer Ingelheim. R. Haviv is the Senior Vice President Clinical and Regulation at Cordio Medical.

References

1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland, DT, Lewis TT, Litchtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report from the American Heart Association. *Circulation.* 2020;141:e139-596.

2. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. *Card Fail Rev.* 2017;3:7-11.

3. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FV, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics – 2019 Update: A Report From the American Heart Association. *Circulation*. 2019;139:e56-528.

4. Amir O, Abraham WT, Azzam ZS, Berger G, Anker SD, Pinney SP, Burkhoff D, Shallom ID, Lotan C, Edelman ER. Remote Speech Analysis in the Evaluation of Hospitalized Patients with Acute Decompensated Heart Failure. *JACC Heart Fail.* 2022;10:41-9.

5. Amir O, Anker SD, Gork I, Abraham WT, Pinney SP, Burkhoff D, Shallom ID, Haviv R, Edelman ER, Lotan C. Feasibility of remote speech analysis in evaluation of dynamic fluid overload in heart failure patients undergoing haemodialysis treatment. *ESC Heart Fail*. 2021;8:2467-72.